Research programme: diabetes therapy - ATON
Alternative Names: Diabetes therapy research programme - ATONLatest Information Update: 28 Sep 2023
Price :
$50 *
At a glance
- Originator Hybrigenics
- Developer ATON
- Class
- Mechanism of Action RAPGEF4 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus